Funding for this research was provided by:
Foundation for the National Institutes of Health (HD036071)
Received: 31 January 2020
Accepted: 10 September 2020
First Online: 29 September 2020
: Dr. Hagerman has received funding from Zynerba, Ovid, and the Azrieli Foundation for treatment studies in fragile X syndrome (FXS). She has also consulted with Zynerba, Ovid, and Fulcrum regarding treatment studies in FXS. Dr. Tassone has received funding from Asuragen and Zynerba for studies in FXS. The funders had no role in study design, data collection, analysis, data interpretation, or manuscript writing. All other authors report no biomedical financial interests or potential conflicts of interest.